NVO NOVO NORDISK A S — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$43.88

Period return

-6.49 (-12.88%)

Volume

14.8M

2026-06-12O $43.94 H $44.6 L $43.72 C $43.88MA5 $42.77MA20 $43.86MA60 $41.42MA120 $45.45

6M · 124 barsYahoo Finance · USD2025-12-15 → 2026-06-12

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 03. 02.MediumHOLD3 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2026. 02. 24.MediumHOLD4 months ago
JP Morgan: Neutral
US analyst rating / recommendation change.
2026. 01. 09.MediumBUY5 months ago
CICC: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $46.87 · 12 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sector: Healthcare
Industry: Drug Manufacturers - General
HQ: Bagsvaerd, Denmark
Fiscal year end: —
Employees: 67,900
IPO date: —

2025. 12. 08.MediumHOLD6 months ago

Argus Research: Hold